Wednesday, 13 May 2015
At AstraZeneca, we are passionate about personalised healthcare because we believe in the benefits it can deliver. You can see this reflected in our pipeline, where 80% of drug projects have a personalised healthcare approach. Delivering the right drug to the right patient at the right time will benefit patients, payers and healthcare systems broadly. Today we are sharing two pieces of news which illustrate how we are following the science, partnering with the best organisations and harnessing the latest technology to deliver targeted medicines to patients. The first is an agreement with the diagnostics division of Abbott to develop a companion diagnostic which will identify patients with severe asthma who may benefit from treatment with tralokinumab, our phase III asthma investigational medicine. The second is a unique research collaboration with the Montreal Heart Institute, a world-leading genomics centre, with whom we will sequence the genomes of 80,000 tissue and blood samples donated by patients who have previously enrolled in clinical trials with us. By sequencing their genomes we will learn more about cardiovascular disease and diabetes, the complications of these diseases and response to treatment. Learn more about these collaborations by watching our video.